Silverback Therapeutics raises $78.5M Series B led by U.S. Venture Partners to advance ImmunoTAC and start SBT6050 clinical trials

Seattle biotech Silverback Therapeutics raised $78.5 million in a Series B to advance its ImmunoTAC platform for targeted, systemically delivered therapies and plans clinical investigation of lead candidate SBT6050 this year.

No comments yet.